18 F‐fluoro‐ethyl‐tyrosine PET co‐registered with magnetic resonance imaging (MRI) in patients with persisting acromegaly
Authors' conclusion
In patients with persisting acromegaly without a clear surgical target on MRI, FET-PET/MRICR is a new tracer to provide additional information to aid decision-making by the multidisciplinary pituitary team.
Study context
- Population
- Patients with insufficiently controlled (persistent) acromegaly referred to evaluate surgical options, where MRI alone and multidisciplinary team evaluation did not provide sufficient clarity to proceed to surgery
- Participants
- 10 patients
- Outcome
- FET-PET/MRICR findings
Main finding
As reported in the abstract
- Suspicious (para)sellar tracer uptake
- all patients
- Fully concordant with conventional MRI
- 5 patients
- Partially concordant with conventional MRI
- 1 patient
- Suggestive new foci identified
- 4 patients
- Findings confirmed intraoperatively among operated patients
- 7 of 9 (78%)
- Findings also confirmed histologically
- 6 (67%)
Observational data: associations, not effects.
Further findings
Treatment
- Surgical re-exploration
- 9 patients (total resection (6), debulking (2), diagnosis (1))
- Radiation therapy
- 1 patient
Biochemical and clinical outcome
- IGF-1 decreased significantly
- 8 patients (89%)
- Clinical improvement
- all patients
- Complete biochemical remission
- 3 patients (50% of procedures in which total resection was anticipated feasible)
- Biochemistry improved
- 5 patients
- Biochemistry unchanged
- 1 patient
Overall outcome · 6 months
Patients
- Optimal outcome (intended goal achieved without permanent complications)
- 6 (67%)
- Intermediate outcome (goal not achieved, no complications)
- 3
Safety
- Permanent complications
- 0
Original publication
18 F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly. Clin Endocrinol (Oxf). Published 31 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →